A multicenter phase II study of docetaxel/gemcitabine weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): Preliminary results of the 02-02 Groupe Francais de Pneumo-Cancerologie (GFPC) study